These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10599937)

  • 21. Hazardous side effects of the phenothiazine drugs.
    Masłowski J
    Bull Inst Marit Trop Med Gdynia; 1987; 38(3-4):220-3. PubMed ID: 2906257
    [No Abstract]   [Full Text] [Related]  

  • 22. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results.
    Kalachnik JE; Harder SR; Kidd-Nielsen P; Errickson E; Doebler M; Sprague RL
    Psychopharmacol Bull; 1984; 20(1):27-32. PubMed ID: 6144132
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dimethylaminoethanol in the treatment of neuroleptic-induced tardive dyskinesia].
    Lambert PA; Wolff P; de Maximy B; Ghenim A
    Ann Med Psychol (Paris); 1978 Apr; 136(4):625-9. PubMed ID: 31832
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
    Bona JR
    J Clin Psychopharmacol; 2006 Apr; 26(2):215-6. PubMed ID: 16633158
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypothermia caused by antipsychotic drugs in a schizophrenic patient.
    Noto T; Hashimoto H; Sugae S; Okamoto K; Nakao J; Kamimura H; Nakajima T
    J Clin Psychiatry; 1987 Feb; 48(2):77-8. PubMed ID: 3804993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment.
    Casey DE; Povlsen UJ; Meidahl B; Gerlach J
    Psychopharmacol Bull; 1986; 22(1):250-3. PubMed ID: 2873612
    [No Abstract]   [Full Text] [Related]  

  • 27. Atypical neuroleptic malignant syndrome with long-term clozapine.
    Corallo CE; Ernest D
    Crit Care Resusc; 2007 Dec; 9(4):338-40. PubMed ID: 18052897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic malignant syndrome while on tiapride treatment.
    Duarte J; Campos JM; Cabezas C; Sagredo V; Cortina J; Clavería LE
    Clin Neuropharmacol; 1996 Dec; 19(6):539-40. PubMed ID: 8937795
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of propranolol in neuroleptic-induced akathesia.
    Adler L; Angrist B; Peselow E; Corwin J; Rotrosen J
    J Clin Psychopharmacol; 1985 Jun; 5(3):164-6. PubMed ID: 2860136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuroleptic malignant syndrome in users of risperidone].
    Gerritsen AA; de Jonghe-Rouleau AP; Stienstra-Liem LH
    Ned Tijdschr Geneeskd; 2004 Sep; 148(37):1801-4. PubMed ID: 15495506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic malignant syndrome.
    Mooney RP; Hasan MK
    W V Med J; 1990 Mar; 86(3):95-8. PubMed ID: 1969191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurotensin: perchance an endogenous neuroleptic?
    Nemeroff CB
    Biol Psychiatry; 1980 Apr; 15(2):283-302. PubMed ID: 6106513
    [No Abstract]   [Full Text] [Related]  

  • 33. A Case of neuroleptic malignant syndrome accompanied to an atypical antipsychotic agent: risperidone.
    Pasa S; Sayhan MB; Boyraz T; Urakci Z; Altintas A
    Neurotoxicology; 2008 Jul; 29(4):750-1. PubMed ID: 18539333
    [No Abstract]   [Full Text] [Related]  

  • 34. [Occurrence of tardive extrapyramidal symptoms in schizophrenic patients undergoing prolonged neuroleptic treatment].
    Rybakowski J; Jaracz J; Lis B; Milewska G; Lezańska M
    Psychiatr Pol; 1979; 13(5):479-85. PubMed ID: 42096
    [No Abstract]   [Full Text] [Related]  

  • 35. Does smoking reduce the risk of neuroleptic parkinsonoids?
    Wagner B; Wolf GK; Ulmar G
    Pharmacopsychiatry; 1988 Nov; 21(6):302-3. PubMed ID: 2907632
    [No Abstract]   [Full Text] [Related]  

  • 36. Ionized calcium and neuroleptic-induced extrapyramidal symptoms.
    Kuny S; Binswanger U
    Pharmacopsychiatry; 1988 Nov; 21(6):300-1. PubMed ID: 2907631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
    Bottlender R; Jäger M; Hofschuster E; Dobmeier P; Möller HJ
    Pharmacopsychiatry; 2002 May; 35(3):119-21. PubMed ID: 12107858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic treatment of alcohol hallucinosis: case series.
    Soyka M; Täschner B; Clausius N
    Pharmacopsychiatry; 2007 Nov; 40(6):291-2. PubMed ID: 18030655
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinico-therapeutic observations in the neuroleptic malignant syndrome].
    Grecu G; Grecu-Gaboş M; Nireşteanu A; Grecu-Gaboş I
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1989; 34(4):267-76. PubMed ID: 2577227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for the neuroleptic malignant syndrome.
    Kirkpatrick B; Edelsohn GA
    Psychiatr Med; 1984 Dec; 2(4):371-81. PubMed ID: 6152857
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.